Here is the design of a clinical trial:

Official Title: A Prospective Multi-center Open-label Controlled Trial of Comparison 3 vs 12 Months of Dual Anti-Platelet Therapy After Implantation of Firehawk Sirolimus Target- Eluting Stent in Patients With Stable Coronary Artery Disease

Included conditions:
- Drug-Eluting Stents
- Percutaneous Coronary Intervention

Study Armgroups:
- {'label': '3 months DAPT Intervention', 'type': 'ACTIVE_COMPARATOR', 'description': 'After implantation of Firehawk coronary stents, all subjects in intervention group will be given dual anti-platelet therapy (DAPT) including aspirin and thienopyridines (clopidogrel or ticagrelor)for 3 months.', 'interventionNames': ['Drug: 3 months DAPT']}
- {'label': '12 months DAPT Intervention', 'type': 'ACTIVE_COMPARATOR', 'description': 'After implantation of Firehawk coronary stents, all subjects in control group will be given dual anti-platelet therapy (DAPT) including aspirin and thienopyridines (clopidogrel or ticagrelor)for 12 months.', 'interventionNames': ['Drug: 12 months DAPT']}

Interventions:
- {'type': 'DRUG', 'name': '3 months DAPT', 'description': 'Subjects will continue DAPT with P2Y12 inhibitors and Aspirin (ASA) up to 90 days, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge.', 'armGroupLabels': ['3 months DAPT Intervention'], 'otherNames': ['Ticagrelor (180 mg/day) or Clopidogrel (75 mg/day)']}
- {'type': 'DRUG', 'name': '12 months DAPT', 'description': 'Subjects will continue DAPT with P2Y12 inhibitors and Aspirin (ASA) up to 360 days, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge.', 'armGroupLabels': ['12 months DAPT Intervention'], 'otherNames': ['Ticagrelor (180 mg/day) or Clopidogrel (75 mg/day)']}

Primary Outcomes:
- {'measure': 'Net Adverse Clinical and Cerebral Events (NACCE)', 'description': 'A composite of all-cause death, MI, cerebral vascular accident (CVA) and major bleeding at 18 months', 'timeFrame': 'At 18 months after index procedure'}

Please estimate the sample size based on the assumption: 
Power of 80.2%, 1-sided type I error rate of 0.025, and 5% loss to follow-up.
Sample size calculations
          Based on the event rates and previous data involving a real-world patient population treated with DES,8 18 24â27 we predicted the NACCE rates of the 3-month DAPT group and the 12-month DAPT group to be at least 10.0% at 18 months after the index PCI. The non-inferiority margin is of 3.5%. We estimated that with a total of 2446 patients (1223 per group), the power of the study would be at 80.2% to detect non-inferiority with a 1-sided type I error rate of 0.025, assuming that 5% of patients would be lost to follow-up.